

We claim:

- 1) A DNA molecule comprising a nucleotide sequence of at least 600 consecutive residues encoding a polypeptide substantially corresponding to SEQ ID NO:2 modified by the elimination of from one to nine inclusive glycosylation sites.**
- 2) The DNA molecule of Claim 1, comprising a nucleotide sequence of SEQ ID NO:5 or SEQ ID NO:6.**
- 3) The DNA molecule of Claim 2 wherein the SEQ ID NO is 6.**
- 4) The DNA molecule of Claim 3, said nucleotide sequence encoding a Region 1 peptide.**
- 5) The DNA molecule of claim 4, said nucleotide sequence operatively linked in a replicon.**
- 6) The DNA molecule of claim 3, said nucleotide sequence encoding a Region IV peptide.**
- 7) The DNA molecule of claim 6, said nucleotide sequence operatively linked in a replicon.**
- 8) The DNA molecule of claim 3, said nucleotide sequence encoding a Region II or Region III peptide.**
- 9) The DNA molecule of claim 8, said nucleotide sequence operatively linked in a replicon.**
- 10) A polypeptide molecule comprising a sequence substantially corresponding to at least 200 consecutive amino acid residues of SEQ ID NO:3, wherein at least one N-linked glycosylation site is eliminated by an amino acid substitution.**
- 11) The polypeptide molecule of Claim 10 wherein from one to nine inclusive residues of said sequence is substituted with substituting residues, said substituted residues selected from the group consisting of T³²⁰, N³³⁰, T³⁵⁹, S⁵⁹¹, N⁶⁰², N⁶⁹¹, S⁷⁰¹, S⁷⁸⁵, and T¹⁰⁵⁸.**
- 12) The polypeptide of claim 11, said substituting residues being Alanine.**

- 13) The polypeptide of claim 12, comprising a Region I peptide.
- 14) The polypeptide of claim 13 comprising SEQ ID NO:4.
- 15) The polypeptide of claim 12 comprising a Region IV peptide.
- 16) The polypeptide of claim 15 comprising SEQ ID NO:10.
- 17) The polypeptide of claim 12 comprising a Region II or Region III peptide.
- 18) The polypeptide of claim 17 comprising SEQ ID NO:8 or SEQ ID NO:9.
- 19) A vaccine for the prevention, attenuation or treatment of Severe Acute Respiratory Syndrome (SARS) in a mammal comprising the DNA molecule of Claim 2.
- 20) A vaccine for the prevention, attenuation or treatment of Severe Acute Respiratory Syndrome (SARS) in a mammal comprising the polypeptide of Claim 10.
- 21) An antibody against the polypeptide of Claim 10
- 22) The antibody of Claim 20 wherein said antibody is monoclonal.